Annual report pursuant to Section 13 and 15(d)

SUBSEQUENT EVENT

v3.19.3.a.u2
SUBSEQUENT EVENT
12 Months Ended
Dec. 31, 2019
SUBSEQUENT EVENT  
SUBSEQUENT EVENT

15. SUBSEQUENT EVENT

 

In January 2020, we received EC approval of our MAA for fostamatinib for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments. With this approval, we received in February 2020 a $20.0 million payment, which is comprised of a $17.5 million payment for EMA approval of fostamatinib for the first indication and a $2.5 million creditable advance royalty payment, based on the terms of our collaboration agreement with Grifols. The above milestone payment will be allocated to the distinct performance obligation in the collaboration agreement with Grifols.